The aim of this study is to have those patients taking part in the Clinical trial-: A Multicentre, Double-Blind, Placebo-Controlled, Pivotal Study of the Efficacy and Safety of Oral Theobromine in the Management of Cough. Complete the Hull Airway Reflux Questionnaire (HARQ) at randomisation and repeat the questionnaire at the end of the 14 day treatment period. The investigators hope to demonstrate a clinically significant change in HARQ scores of at least 16 points from before and after treatment. Furthermore the investigators would hope to show a significantly improved HARQ score in patients on the BC036 arm of the study compared to the placebo arm.
Study Type
OBSERVATIONAL
Enrollment
57
Hull and East Yorkshire Hospitals Trust
Cottingham, East Riding Of Yorkshire, United Kingdom
Hull Airway Reflux Questionnaire score
The primary objective is to evaluate the effectiveness of HARQ in measuring a clinically significant change in HARQ score from baseline following 14 days treatment.
Time frame: baseline and 2 weeks later
HARQ SCORES
The Key secondary endpoint will be to evaluate ability of HARQ in demonstrating a clinically significant change in score from baseline in the BC036 arm compared to Placebo arm of main study.
Time frame: baseline and 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.